Latest Headlines

31. OCEAN Dx Rapid Diagnostic Test For Sepsis Matched Gold Standard During A Clinical Evaluation Study 11/17/2025

    OCEAN Dx, a pioneer in rapid diagnostic solutions, announced the successful completion of a clinical evaluation study for its innovative rapid diagnostic test for sepsis.

32. Trinity Biotech Announces Collaboration To Advance Epigenetic Analysis For Epicapture Prostate Cancer Test 11/14/2025

    Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic collaboration with a leading bioinformatics company to conduct advanced analysis on clinical trial data for EpiCapture, the company’s PCR-based epigenetic liquid biopsy test for monitoring the risk of prostate cancer progressing to more aggressive forms of the disease.

33. Labcorp To Acquire Select Parkview Health Laboratory Outreach Assets 11/13/2025

    Labcorp a global leader of innovative and comprehensive laboratory services, and Parkview Health, one of the fastest growing health systems in the Midwest, today announced a strategic agreement for Labcorp to acquire select assets of the health system’s outreach laboratory services that provides high-quality testing across Indiana and northwest Ohio.

34. Thermo Fisher Scientific Receives 510(k) Clearance In The United States For EXENT System^* To Aid In The Diagnosis Of Multiple Myeloma 11/12/2025

    Thermo Fisher Scientific Inc. the world leader in serving science, today announced 510(k) clearance of the EXENT Analyser and Immunoglobulin Isotypes (GAM) Assay^**, a first-of-its-kind automated platform for clinical laboratories.

35. Microbix Partners With SEKISUI Diagnostics To Support COVID/Flu Tests 11/12/2025

    Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and SEKISUI Diagnostics, LLC (SEKISUI), a global manufacturer of innovative diagnostic tests, reagents, diagnostic systems, and raw materials, announce that Microbix external third-party quality assessment products (REDx™FLOQ® QAPs®) will be used to support SEKISUI’s U.S. commercialization of the molecular point-of-care assay for diagnosis of COVID/Flu A/Flu B using the Metrix® platform from Aptitude Medical Systems, Inc. (Aptitude).

36. Mainz Biomed Showcases Innovative Cancer Detection Solutions At MEDICA 2025 11/12/2025

    Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in MEDICA 2025, one of the world’s leading healthcare trade shows, taking place from 17–20 November, 2025, in Düsseldorf, Germany.

37. Pillar Biosciences Enables Rapid, Localized Tumor Profiling Of Lymphoid Malignancies With Launch Of New Kitted NGS Panel 11/12/2025

    Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the launch of oncoReveal® Lymphoid, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories to perform rapid tumor profiling of lymphoid malignancies.

38. EXoPERT Joins JLABS TMC, Johnson & Johnson's Global Incubator Network 11/12/2025

    EXoPERT, a biotechnology company pioneering AI-powered exosome-based liquid biopsy diagnostics for multi-cancer early detection, is excited to announce that it has joined Johnson & Johnson's global incubator network, JLABS, as a resident of JLABS TMC.

39. BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements With Fidelion Diagnostics For Southeast Asia MRD Commercialization 11/12/2025

    BioNexus Gene Lab Corp. (“BGLC,” Nasdaq: BGLC) today announced it has entered into definitive agreements with Fidelion Diagnostics Pte. Ltd. (“Fidelion”) and Tongshu Biotechnology (Hong Kong) Co., Limited (“Tongshu”), among other parties, to commercialize VitaGuard™, a high-fidelity, tumor-naïve liquid-biopsy platform for minimal residual disease (MRD).

40. GenomOncology Partners With Glioblastoma Foundation To Accelerate Precision Glioblastoma Brain Cancer Treatment 11/11/2025

    GenomOncology today announced a strategic partnership with the Glioblastoma Foundation to transform genomic testing for the nation's most aggressive brain cancer, glioblastoma.